TickerTalks
Browse all tickers →
TickerTalks›$QURE
QUQURE

uniQure N.V.

Rising onWhy it's trendingStrong bullish X conversationBacked by solid revenue growth
$QURE·$3.0B·Biotechnology·Healthcare
$43.63+3.4%YTD+75.6%1Y+213.4%
Mentions · last 7 days
2026-07-26: 9 posts2026-07-27: 29 posts2026-07-28: 41 posts2026-07-29: 105 posts2026-07-30: 57 posts2026-07-31: 32 posts2026-08-01: 10 posts283+25%
Price updated 2d ago·X counts updated 1d ago
QUQURE
$QUREuniQure N.V.
$43.63+3.41%283 posts+25%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $QURE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-07-31

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

uniQure up 192% TTM on AMT-130 Huntington's — Q3 regulatory filing, 4-year data readout, cash just raised via $225M offering.

uniQure is a clinical-stage gene therapy developer whose lead asset AMT-130 is a one-time intracranial gene therapy for Huntington's disease — a devastating neurodegenerative disease with no approved disease-modifying treatment. The 192% TTM move reflects that this may become the first commercial gene therapy for the condition.

  • The Q3 catalysts are specific: US and UK regulatory submissions for AMT-130 are on track for Q3, plus topline four-year data from the Phase 1/2 study in ~12 patients is expected — the four-year durability data is exactly what the FDA and payers need to see to justify a one-time-dose disease-modifying premium price.
  • The regulatory-alignment signals are real: two CTGTAC briefing documents landed in 48 hours (favorable prespecification + mechanism-of-action arguments vs the CAPR briefing), the NIHR UK spotlighted AMT-130 in its annual report, and a SVP of Commercial was recently hired at ~$500K salary — the commercial hire is what companies do when they've received positive Type B meeting minutes and are preparing for launch.
  • The financing overhang was addressed: uniQure just priced a $225M public offering at $45.50 per share on June 23, raising $211.5M net — meaning the balance sheet now supports the pivotal readout and initial commercial launch without needing another raise mid-flight. Insider tape: officer Kapusta sold $952K on July 2, small relative to the offering size.

The Nov 9 Q3 print is a supporting event — the real catalysts are the Q3 regulatory filings (US + UK) and the four-year Phase 1/2 topline data. A positive four-year durability readout with regulatory-alignment commentary is a re-rating catalyst; any efficacy or safety concern at the four-year mark is a 40-60% drawdown. Binary at the readout; funded through the launch.

Agrees with X sentimentX captures the setup accurately — Q3 regulatory submissions, four-year Phase 1/2 data expected, favorable CTGTAC briefing docs, SVP Commercial hire as positive Type B meeting signal, NIHR UK spotlight. Fair take. The recent $225M financing is dilutive but funded — the crowd has moved past it because the runway question is settled.

What to watch: Q3 US and UK regulatory submissions for AMT-130, plus topline four-year Phase 1/2 data — a positive four-year durability readout with regulatory-alignment commentary is the re-rating catalyst. Any efficacy or safety concern is a 40-60% drawdown.

On the calendar: 2026-11-09 — Q3 earnings (real catalyst is the AMT-130 4-year readout)

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment86 posts analyzed · as of 2026-08-01

Sentiment on uniQure is decidedly bullish and event-driven. Bulls cite Wells Fargo's fresh $75 PT hike, the September readout window for four-year AMT-130 data in Huntington's, US/UK regulatory submissions on track for Q3, and a flurry of senior-commercial hires suggesting internally positive June Type-B meeting minutes. Contrasting the CAPR advisory-committee disaster, bulls emphasize QURE's pre-specified SAP and April 2025 FDA alignment. Aggressive August $50 call flow (~2,300 contracts) is being celebrated. Confidence in Matt Kapusta and management runs through the whole sample.

Read the AI verdict + X sentiment for $QURE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Gene therapy company with hemophilia B therapy (etranacogene) in pivotal trials and AMT-130 for Huntington's disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $QURE.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $QURE

Neutral — Gene therapy company with hemophilia B therapy (etranacogene) in pivotal trials and AMT-130 for Huntington's disease; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-14.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-26.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
167.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-146%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
74.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$-1.22$-0.82-48.4%
Q1 2026May 5, 2026$-0.85$-0.88+3.4%
Q4 2025Mar 2, 2026$-0.56$-0.93+39.8%
Q3 2025Nov 10, 2025$-1.38$-0.85-62.4%
Next earningsMon, Nov 9·consensus EPS $-0.90

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.6M+127.3%93.9%-1243%$-0.85$-38.4M
Q4 FY25$5.6M+6.6%38.8%-937%$-0.59$-77.2M
Q3 FY25$3.7M+61.8%89.2%-1379%$-1.38$-16.3M
Q2 FY25$5.3M-52.7%87.5%-834%$-0.69$-40.2M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$21.7M$15.8M – $32.4M-$3.82-$3.99 – -$3.725
FY27$134.4M$81.7M – $223.1M-$2.96-$3.35 – -$2.447
FY28$408.6M$98.6M – $791.8M-$0.95-$4.48 – $4.106
FY29$652.4M$193.9M – $1.4B$1.49$0.13 – $3.625
FY30$881.9M$262.1M – $1.8B$4.17$0.36 – $10.103

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.56%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+18.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+52.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 62.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.905-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Matthew C KapustaCEO21.1K sh$952KSellJun 30Jack KayeDirector21.2K sh$983KSellJun 30Walid Abi-saabChief Medical Officer30.0K sh$1.4MSellJun 26Walid Abi-saabChief Medical Officer1.4K sh$67KSellJun 25Matthew C KapustaCEO28.7K sh$1.4MSellJun 24Matthew C KapustaCEO6.7K sh$335KSellJun 18Matthew C KapustaCEO41.7K sh$2.1MSellJun 17Jack KayeDirector5.3K sh$225KSellJun 17Madhavan BalachandranDirector11.7K sh$526KSellJun 17Matthew C KapustaCEO164.4K sh$7.3M
1–10 of 26
+ 24 other (13 exempts · 11 awards) in window

See when $QURE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 248-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

uniQure N.V. entered an underwriting agreement on June 23, 2026 for a public offering of 4,945,055 ordinary shares at $45.50/share. The underwriter greenshoe option (741,758 additional shares) was exercised in full on June 24, 2026. Total net proceeds estimated at ~$242.7M after underwriting discounts and expenses. Material — confirms the capital raise details; proceeds fund gene therapy pipeline and potential commercialization of DT120.

424B5Prospectus supplement (offering)Jun 24424B5
AI summary

uniQure N.V. priced a public offering of 4,945,055 ordinary shares at $45.50 per share on June 23, 2026, raising ~$225M gross (~$211.5M net), with underwriters led by Leerink Partners. The greenshoe option of 741,758 additional shares was exercised in full on June 24, 2026, bringing total net proceeds to ~$242.7M. Material dilution event at a discount to the prior day's close of $49.04; proceeds will fund gene therapy R&D and potential DT120 commercialization preparation.

424B5Prospectus supplement (offering)Jun 22424B5
AI summary

QURE filed a 424B5 prospectus supplement on 2026-06-22 of 150,000,000 Ordinary Shares at $44.39 per share. This represents dilution happening now.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

The Netherlands ​ ​ ​ 001-36294 ​ ​ ​ N/A disclosed: pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ Item 7.01 Regulation FD Disclosure. On June 19, 2026, uniQure N.V. (the “ Company ”) issued a press release announcing preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. ​ The information provided in th.

8-KOfficer or director changeJun 158-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

uniQure N.V. filed an 8-K (Items 5.02, 5.03, 5.07) dated June 10, 2026, reporting officer/director changes, an amendment to articles of incorporation or bylaws, and shareholder vote results from its annual meeting. The excerpt is cover-page only with no specifics on which directors/officers changed or what bylaw amendment was approved. The combination of governance changes and a charter amendment may reflect board refreshment or structural changes relevant to uniQure's clinical-stage gene therapy programs.

8-KPress release / Reg FDApr 308-K — Item 7.01: Press release / Reg FD
AI summary

uniQure N.V. filed an 8-K under Item 7.01 (Reg FD) on April 30, 2026, furnishing an investor presentation for this Netherlands-based gene therapy company. The excerpt is XBRL boilerplate with no topic or slide content visible. Routine Reg FD disclosure — for a clinical-stage biotech like uniQure, investor presentations often include pipeline updates and clinical data readouts, making the attached exhibit potentially relevant for AMT-130 (Huntington's) development timeline watchers.

3New insider — initial holdingsMar 93
8-KPress release / Reg FDMar 28-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 22 other (11 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Yzacks.com·4d agoHere Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More247wallst.com·4d agouniQure N.V. (QURE) Q2 2026 Earnings Call Transcriptseekingalpha.com·4d agouniQure Q2 Earnings Call Highlightsmarketbeat.com·5d agouniQure (QURE) Reports Q2 Loss, Misses Revenue Estimateszacks.com·5d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$CAPR$IBRX$REGN$AURA$HALO$ALLO$MRNA
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport